Skip to content

Legal and Regulatory Considerations Impacting Oncology Specialty Pharmacy

Legal and Regulatory Considerations Impacting Oncology Specialty Pharmacy
ACPE UAN: 0233-0000-20-05-L03-P | 0.75 contact hours | Knowledge-based

Course Description
Laws and regulations at the state and federal level that impact oncology care, including access to care and costs that are borne by patients. Some of these laws, such as those that address utilization management strategies, are applicable to multiple therapeutic classes. Others, such as oral parity laws as well as a subset of laws addressing utilization management, are specific to oncology. During this session, the current legislative and regulatory landscape regarding the use of utilization management strategies for oncologic treatments will be reviewed.

Learning Objectives
At the completion of this session, participants will be able to:

  1. Describe common provisions of laws and regulations impacting utilization management strategies for oncologic treatments, such as prior authorization and step therapy.
  2. Explain the rationale and impact of oral chemotherapy parity laws.
  3. Describe recent federal guidances and state laws that impact the utilization of biosimilars in oncology.

Faculty

Jeremy Scott, MA
Senior Director of Government Affairs | Powers Pyles Sutter & Verville PC | Washington, District of Columbia

Jeremy Scott is a Senior Director of Government Affairs in the Powers Pyles Sutter & Verville Legislative Practice, where he focuses on health care policy and representing the interests of nonprofit, advocacy, and health organizations. He has extensive experience in and knowledge of the federal public policymaking and legislative and regulatory processes, strategic planning initiatives, and advocacy campaigns.

Prior to joining Powers, Jeremy was Senior Vice President for the District Policy Group, a team within the Government and Regulatory Affairs Practice of Drinker Biddle & Reath LLP, where he counseled clients on various policy and advocacy issues, including advancing authorization legislation, securing federal appropriations support for programmatic funding increases, and working with federal agencies on the implementation of legislation or proposed rules. 

Before his time with Drinker Biddle, Jeremy was the director of public policy for the Tourette Association of America (formerly known as the Tourette Syndrome Association), where he directed and managed the organization’s Washington, D.C., office. Jeremy was responsible for advocating TAA’s legislative agenda on Capitol Hill and before federal agencies. He also gathered grassroots support for legislative issues, including the inclusion of Tourette Syndrome as a disability in the Individuals with Disabilities Education Act. 

In addition, Jeremy worked as a legislative associate with Kinghorn Hilbert & Associates, LLC, (formerly known as Kinghorn & Associates) a government consulting firm in Washington, D.C. Before his position with Kinghorn Hilbert & Associates, Jeremy worked as a legislative correspondent and staff assistant for Senator Mike DeWine (R-Ohio), focusing primarily on health issues related to managed care, Medicare, Medicaid and appropriations.